Search Results - "Darton, Eddie"

O19: Integrated analyses of data from clinical trials of delandistrogene moxeparvovec gene therapy in DMD by O’Rourke, Erin, Proud, Crystal, Zaidman, Craig, Shieh, Perry B., McDonald, Craig, Day, John W., Mason, Stefanie, Guridi, Maitea, Han, Lixin, Yu, Lixi, Reid, Carol, Darton, Eddie, Wandel, Christoph, Richardson, James, Malhotra, Jyoti, Singh, Teji, Rodino-Klapac, Louise, Mendell, Jerry

Get full text

P314: Long-term safety and sustained functional benefit in patients with DMD 4 years post-treatment with delandistrogene moxeparvovec: A phase 1/2a study by O’Rourke, Erin, Mendell, Jerry R., Sahenk, Zarife, Lehman, Kelly J., Lowes, Linda P., Reash, Natalie F., Iammarino, Megan, Alfano, Lindsay, Lewis, Sarah, Church, Kathleen, Shell, Richard, Potter, Rachael A., Griffin, Danielle, Hogan, Mark J., Wang, Shufang, Mason, Stefanie, Darton, Eddie, Rodino-Klapac, Louise

Get full text

Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial by Mendell, Jerry R., Sahenk, Zarife, Lehman, Kelly J., Lowes, Linda P., Reash, Natalie F., Iammarino, Megan A., Alfano, Lindsay N., Lewis, Sarah, Church, Kathleen, Shell, Richard, Potter, Rachael A., Griffin, Danielle A., Hogan, Mark, Wang, Shufang, Mason, Stefanie, Darton, Eddie, Rodino‐Klapac, Louise R.

“…Introduction/Aims Delandistrogene moxeparvovec is indicated in the United States for the treatment of ambulatory pediatric patients aged 4 through 5 years with…”
Get full text

Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy by Mendell, Jerry R., Proud, Crystal, Zaidman, Craig M., Mason, Stefanie, Darton, Eddie, Wang, Shufang, Wandel, Christoph, Murphy, Alexander P., Mercuri, Eugenio, Muntoni, Francesco, McDonald, Craig M.

“…Delandistrogene moxeparvovec is a gene transfer therapy approved in the United States, United Arab Emirates, and Qatar for the treatment of ambulatory patients…”
Get full text

Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR) by Zaidman, Craig M., Proud, Crystal M., McDonald, Craig M., Lehman, Kelly J., Goedeker, Natalie L., Mason, Stefanie, Murphy, Alexander P., Guridi, Maitea, Wang, Shufang, Reid, Carol, Darton, Eddie, Wandel, Christoph, Lewis, Sarah, Malhotra, Jyoti, Griffin, Danielle A., Potter, Rachael A., Rodino‐Klapac, Louise R., Mendell, Jerry R.

“…Objective Delandistrogene moxeparvovec is approved in the USA for the treatment of ambulatory patients (4–5 years) with Duchenne muscular dystrophy. ENDEAVOR…”
Get full text

Integrated Analyses of Data from Clinical Trials of Delandistrogene Moxeparvovec (SRP-9001) in Duchenne Muscular Dystrophy (DMD) (S48.006) by Proud, Crystal, Zaidman, Craig, Shieh, Perry, McDonald, Craig, Day, John, Mason, Stefanie, Guridi, Maitea, Han, Lixin, Yu, Lixi, Reid, Carol, Darton, Eddie, Wandel, Christoph, Richardson, James, Malhotra, Jyoti, Singh, Tejdip, Rodino-Klapac, Louise, Mendell, Jerry

“…Abstract only…”
Get full text

EMBARK, a Phase 3 Trial Evaluating Safety and Efficacy of Delandistrogene Moxeparvovec (SRP- 9001) in Duchenne Muscular Dystrophy (DMD): Study Design and Baseline Characteristics (P5-8.012) by Muntoni, Francesco, Mercuri, Eugenio, Schmidt, Ulrike Schara, Komaki, Hirofumi, Richardson, James, Singh, Tejdip, Guridi, Maitea, Mason, Stefanie, Murphy, Alex, Yu, Lixi, Reid, Carol, Darton, Eddie, Wandel, Christoph, Mendell, Jerry

“…Abstract only…”
Get full text

One-year Data from ENDEAVOR, a Phase 1b Trial of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD) (S48.003) by Zaidman, Craig, Proud, Crystal, McDonald, Craig, Mason, Stefanie, Guridi, Maitea, Wang, Shufang, Reid, Carol, Darton, Eddie, Wandel, Christoph, Lewis, Sarah, Malhotra, Jyoti, Griffin, Danielle, Potter, Rachael, Rodino-Klapac, Louise, Mendell, Jerry

“…Abstract only…”
Get full text

Long-term Safety and Efficacy in Patients with DMD 4 Years Post-Treatment with Delandistrogene Moxeparvovec (SRP-9001) in a Phase 1/2a Study (P3-8.006) by Mendell, Jerry, Sahenk, Zarife, Lehman, Kelly, Lowes, Linda, Reash, Natalie, Iammarino, Megan, Alfano, Lindsay, Lewis, Sarah, Church, Kathleen, Shell, Richard, Potter, Rachael, Griffin, Danielle, Hogan, Mark, Wang, Shufang, Mason, Stefanie, Darton, Eddie, Rodino-Klapac, Louise

“…Abstract only…”
Get full text

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial by Mendell, Jerry R, Muntoni, Francesco, McDonald, Craig M, Mercuri, Eugenio M, Ciafaloni, Emma, Komaki, Hirofumi, Leon-Astudillo, Carmen, Nascimento, Andrés, Proud, Crystal, Schara-Schmidt, Ulrike, Veerapandiyan, Aravindhan, Zaidman, Craig M, Guridi, Maitea, Murphy, Alexander P, Reid, Carol, Wandel, Christoph, Asher, Damon R, Darton, Eddie, Mason, Stefanie, Potter, Rachael A, Singh, Teji, Zhang, Wenfei, Fontoura, Paulo, Elkins, Jacob S, Rodino-Klapac, Louise R

“…Duchenne muscular dystrophy (DMD) is a rare, X-linked neuromuscular disease caused by pathogenic variants in the DMD gene that result in the absence of…”
Get full text